Alirocumab
Alirocumab is a human monoclonal antibody directed at proprotein convertase subtilisin kexin type 9 (PCSK9) and has been shown to reduce low-density lipoprotein (LDL) cholesterol levels.What can Sanquin do for you?
- Measure drug levels of free drug in the serum using an validated ELISA.
- Measure the immunogenicity of alirocumab.
- Provide assay reagents or co-develop novel testing strategies.
- Folllowing ISO, FDA/EMA, RUO guidelines.
Enquire about our drug level and ADA assays by emailing us at [email protected].